Form 4: Puma Biotechnology Director Allison Dorval Granted 27,000 Restricted Stock Units

Puma Biotechnology, Inc. Director Allison Dorval was granted 27,000 Restricted Stock Units (RSUs) on June 11, 2025, increasing her beneficial ownership to 87,000 shares.

Summary

• Allison Dorval, a Director of Puma Biotechnology, Inc. (PBYI), acquired 27,000 shares of Common Stock.
• The transaction occurred on June 11, 2025, and was reported on June 13, 2025.
• The acquisition was in the form of Restricted Stock Units (RSUs) with a price of $0 per unit, indicating a grant.
• These RSUs are set to vest in full on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent on Ms. Dorval's continued service.
• Following this transaction, Ms. Dorval's total beneficial ownership of Puma Biotechnology Common Stock increased to 87,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued director involvement and alignment of interests with shareholders, which is generally viewed favorably.

Positives

• The grant of Restricted Stock Units to Director Allison Dorval aligns her interests more closely with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The increase in beneficial ownership by a director can signal confidence in the company's future prospects.

Future Outlook

The document indicates that the granted Restricted Stock Units will vest on the earlier of the one-year anniversary of the grant date (June 11, 2025) or the date of the annual shareholder meeting following the grant date, subject to continued service.

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across industries, including the biotechnology sector, to incentivize and retain key personnel and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) is a common form of equity compensation for directors and executives in the biotechnology industry, similar to practices at companies like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD), which frequently use RSUs to align management incentives with shareholder value.
• The vesting schedule, tied to continued service and a one-year anniversary or next annual meeting, is typical for such grants, ensuring retention and long-term commitment, comparable to compensation structures seen at peer biotech firms.

Related Party Transactions

• The acquisition of Restricted Stock Units by Allison Dorval, a Director of Puma Biotechnology, Inc., constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's financial interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for equity participation within the company.
• Management: The RSU grant serves as an incentive for the director to remain with the company and contribute to its success.

Next Steps

• The Restricted Stock Units are subject to a vesting schedule, which will occur on the earlier of the one-year anniversary of the grant date (June 11, 2025) or the date of the annual shareholder meeting following the grant date, provided Allison Dorval continues her service with the Issuer.

Key Dates

Keywords

Puma Biotechnology, PBYI, SEC Form 4, Restricted Stock Units, RSU grant, Director compensation, Insider ownership, Equity compensation, Biotechnology, Corporate governance